{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:22:00Z","timestamp":1789017720060,"version":"build-2803163510"},"reference-count":40,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The CD47\/signal regulatory protein \u03b1 pathway is an emerging immune checkpoint that is a new\u00a0therapeutic target. We investigated CD47 expression in diffuse large B-cell lymphoma (DLBCL) of various subtypes and organs. Moreover, the relationship between CD47 expression and genetic alterations was analyzed using panel-based massively parallel sequencing (next-generation sequencing [NGS]). CD8, CD68, and CD47 immunohistochemical staining were performed on 238 patients with DLBCL. CD47 was scored according to intensity on a 5-level scale, and CD8 and CD68 were quantitatively evaluated using QuPath software. Panel-based NGS was performed in 37 patients. In CD8 and CD68 quantitative analyses by organs, intestinal DLBCL showed significantly lower cytotoxic T-cell infiltration than that in others (P\u00a0&amp;lt; .001). The CD47-high group comprised 24 of 58 (41.4%) patients in the group with DLBCL from intestine and 15 of 180 (8.3%) patients in the group with DLBCL from other organs (P\u00a0&amp;lt; .001). The 18q21 gain\/amplification was found in 10 of 37 patients, and all of them were CD47-high. Intestinal CD47-high DLBCL occurred in terminal ileum to ascending colon and was restricted to nongerminal center B-cell type. In the survival analyses, the prognosis of nonintestinal CD47-high DLBCL was poorer than that of intestinal CD47-high DLBCL (P\u00a0= .025). CD47-high DLBCL was closely associated with 18q21 gain\/amplification and showed a high prevalence in intestine. We propose to classify CD47-high DLBCL into intestinal and nonintestinal types. Further studies are necessary to assess whether the constellation of features seen here is reproducible and sufficient to consider primary intestinal DLBCL as a distinct biological entity.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021006305","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T14:13:30Z","timestamp":1651068810000},"page":"6120-6130","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["CD47 overexpression is common in intestinal non-GCB type diffuse large B-cell lymphoma and associated with 18q21 gain"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6089-9340","authenticated-orcid":false,"given":"Junhun","family":"Cho","sequence":"first","affiliation":[{"name":"1Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Eun","family":"Yoon","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2776-4401","authenticated-orcid":false,"given":"Seok Jin","family":"Kim","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4383-0579","authenticated-orcid":false,"given":"Young Hyeh","family":"Ko","sequence":"additional","affiliation":[{"name":"3Department of Pathology, Korea University Guro Hospital, Seoul, Korea"},{"name":"4Department of Pathology, Hanyang University Hospital, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5400-0466","authenticated-orcid":false,"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,12,14]]},"reference":[{"key":"2023053018344761700_bib1","author":"Swerdlow","year":"2017","edition":"4th ed."},{"issue":"18","key":"2023053018344761700_bib2","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2023053018344761700_bib3","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1172\/JCI129206","article-title":"Immunotherapy of lymphomas","volume":"130","author":"Ansell","year":"2020","journal-title":"J\u00a0Clin Invest"},{"key":"2023053018344761700_bib4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3389\/fonc.2018.00351","article-title":"Cancer immunotherapy in diffuse large B-cell lymphoma","volume":"8","author":"Zhang","year":"2018","journal-title":"Front Oncol"},{"issue":"448","key":"2023053018344761700_bib5","first-page":"448","article-title":"Lymphoma immunotherapy: current status","volume":"6","author":"Zappasodi","year":"2015","journal-title":"Front Immunol"},{"issue":"4","key":"2023053018344761700_bib6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"6 Pt 1","key":"2023053018344761700_bib7","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1083\/jcb.111.6.2785","article-title":"Integrin-associated protein: a 50-kD plasma membrane antigen physically and functionally associated with integrins","volume":"111","author":"Brown","year":"1990","journal-title":"J\u00a0Cell Biol"},{"key":"2023053018344761700_bib8","doi-asserted-by":"crossref","first-page":"614619","DOI":"10.1155\/2013\/614619","article-title":"CD47: a cell surface glycoprotein which regulates multiple functions of hematopoietic cells in health and disease","volume":"2013","author":"Oldenborg","year":"2013","journal-title":"ISRN Hematol"},{"issue":"6","key":"2023053018344761700_bib9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nri1859","article-title":"The SIRP family of receptors and immune regulation","volume":"6","author":"Barclay","year":"2006","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2023053018344761700_bib10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell"},{"issue":"5","key":"2023053018344761700_bib11","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"issue":"17","key":"2023053018344761700_bib12","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1073\/pnas.1121623109","article-title":"The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors","volume":"109","author":"Willingham","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2023053018344761700_bib13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1040-8428(01)00203-7","article-title":"A\u00a0potential role of macrophage activation in the treatment of cancer","volume":"44","author":"Klimp","year":"2002","journal-title":"Crit Rev Oncol Hematol"},{"issue":"47","key":"2023053018344761700_bib14","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"issue":"10","key":"2023053018344761700_bib15","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1158\/2326-6066.CIR-18-0781","article-title":"CD47 expression defines efficacy of rituximab with CHOP in non-germinal center B-cell (Non-GCB) diffuse large B-cell lymphoma patients (DLBCL), but not in GCB DLBCL","volume":"7","author":"Bouwstra","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"2023053018344761700_bib16","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1158\/1078-0432.CCR-20-3706","article-title":"Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies","volume":"27","author":"Ansell","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2023053018344761700_bib17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"1","key":"2023053018344761700_bib18","doi-asserted-by":"crossref","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep"},{"key":"2023053018344761700_bib19","doi-asserted-by":"crossref","first-page":"baz146","DOI":"10.1093\/database\/baz146","article-title":"KRGDB: the large-scale variant database of 1722 Koreans based on whole genome sequencing","volume":"2020","author":"Jung","year":"2020","journal-title":"Database"},{"issue":"5","key":"2023053018344761700_bib20","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"4","key":"2023053018344761700_bib21","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"a probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"issue":"26","key":"2023053018344761700_bib22","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.1200\/JCO.2005.05.011","article-title":"Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma","volume":"23","author":"Farinha","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2023053018344761700_bib23","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1182\/blood.V93.11.3601","article-title":"The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas","volume":"93","author":"Dierlamm","year":"1999","journal-title":"Blood"},{"issue":"9","key":"2023053018344761700_bib24","doi-asserted-by":"crossref","first-page":"a003004","DOI":"10.1101\/cshperspect.a003004","article-title":"Antigen receptor signaling to NF-kappaB via CARMA1, BCL10, and MALT1","volume":"2","author":"Thome","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"3","key":"2023053018344761700_bib25","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/ni1561","article-title":"T\u00a0cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20","volume":"9","author":"Coornaert","year":"2008","journal-title":"Nat Immunol"},{"issue":"11","key":"2023053018344761700_bib26","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1182\/blood-2002-10-3236","article-title":"MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma","volume":"101","author":"Sanchez-Izquierdo","year":"2003","journal-title":"Blood"},{"issue":"7","key":"2023053018344761700_bib27","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2004-06-2297","article-title":"MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells","volume":"105","author":"Ho","year":"2005","journal-title":"Blood"},{"issue":"2","key":"2023053018344761700_bib28","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/hep.27859","article-title":"Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice","volume":"62","author":"Lo","year":"2015","journal-title":"Hepatology"},{"issue":"1","key":"2023053018344761700_bib29","doi-asserted-by":"crossref","first-page":"14802","DOI":"10.1038\/ncomms14802","article-title":"A\u00a0CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer","volume":"8","author":"Betancur","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"2023053018344761700_bib30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrc2986","article-title":"For better or for worse: the role of Pim oncogenes in tumorigenesis","volume":"11","author":"Nawijn","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2023053018344761700_bib31","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13045-014-0095-z","article-title":"Pim kinases in hematological malignancies: where are we now and where are we going?","volume":"7","author":"Mondello","year":"2014","journal-title":"J\u00a0Hematol Oncol"},{"issue":"4","key":"2023053018344761700_bib32","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/cdd.2009.174","article-title":"Pim-1 controls NF-kappaB signalling by stabilizing RelA\/p65","volume":"17","author":"Nihira","year":"2010","journal-title":"Cell Death Differ"},{"issue":"5","key":"2023053018344761700_bib33","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3324\/haematol.12057","article-title":"Deutsche Krebshilfe Network Project \u201cMolecular Mechanisms in Malignant Lymphomas\u201d. Gain of chromosome region 18q21 including the MALT1 gene is associated with the activated B-cell-like gene expression subtype and increased BCL2 gene dosage and protein expression in diffuse large B-cell lymphoma","volume":"93","author":"Dierlamm","year":"2008","journal-title":"Haematologica"},{"issue":"12","key":"2023053018344761700_bib34","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","article-title":"Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B\u00a0cell lymphoma cells","volume":"194","author":"Davis","year":"2001","journal-title":"J\u00a0Exp Med"},{"issue":"7247","key":"2023053018344761700_bib35","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature07968","article-title":"Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma","volume":"459","author":"Compagno","year":"2009","journal-title":"Nature"},{"issue":"2","key":"2023053018344761700_bib36","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.immuni.2017.07.016","article-title":"Dendritic cells but not macrophages sense tumor mitochondrial DNA for cross-priming through signal regulatory protein \u03b1\u00a0signaling","volume":"47","author":"Xu","year":"2017","journal-title":"Immunity"},{"issue":"4","key":"2023053018344761700_bib37","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1084\/jem.194.4.541","article-title":"CD47 (integrin-associated protein) engagement of dendritic cell and macrophage counterreceptors is required to prevent the clearance of donor lymphohematopoietic cells","volume":"194","author":"Blazar","year":"2001","journal-title":"J\u00a0Exp Med"},{"issue":"27","key":"2023053018344761700_bib38","doi-asserted-by":"crossref","first-page":"11103","DOI":"10.1073\/pnas.1305569110","article-title":"Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response","volume":"110","author":"Tseng","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"2023053018344761700_bib39","doi-asserted-by":"crossref","first-page":"e0137345","DOI":"10.1371\/journal.pone.0137345","article-title":"Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"2023053018344761700_bib40","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1182\/blood-2010-06-288480","article-title":"Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone","volume":"117","author":"Kim","year":"2011","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/24\/6120\/2054453\/blooda_adv-2021-006305-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/24\/6120\/2054453\/blooda_adv-2021-006305-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T18:36:59Z","timestamp":1685471819000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/24\/6120\/485064\/CD47-overexpression-is-common-in-intestinal-non"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,14]]},"references-count":40,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2022,12,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021006305","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,14]]}}}